1. Generics Bulletin
  2. >>Products
  3. >>Biosimilars

Coherus Has $2.2bn Revenue Ambition By 2026 – But Humira Is Key

Yusimry Adalimumab Biosimilar Uptake Is ‘Key Swing’ For Company Projections

 
• By Dean Rudge

During the company’s landmark first annual analyst day, Coherus BioSciences management spoke at length about its ambitions for Coherus to generate north of $2bn in revenues by 2026, with much riding on how it fares in the impending biosimilar Humira market.

prices for drugs
Coherus has provided a long-term revenue guide • Source: Alamy

Launching three new biosimilar products and its toripalimab novel immuno-oncology product in the next 15 months is expected to deliver revenues of at least $1.2bn by 2026, Coherus BioSciences, Inc. has disclosed as part of the company’s landmark first annual analyst day.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Biosimilars

More from Products

J&J Denied Injunction Over Private-Label Ustekinumab In US

 
• By Dave Wallace

Stelara originator J&J has been denied in its initial attempt to prevent Samsung Bioepis and ustekinumab biosimilar partner Sandoz from selling a private-label version of the product through a PBM in the US.

UK Forxiga SPCs Wiped Out As Trio Succeed With Plausibility Attack

 
• By Dean Rudge

Generic competition to AstraZeneca’s blockbuster SGLT2 inhibitor Forxiga (dapagliflozin) treatment for diabetes may hit England and Wales earlier than 2028 after a pair of SPCs were invalidated following proceedings initiated by a trio of generics manufacturers.

What’s Next? Five Things To Look Out For In May

 
• By Dean Rudge

Generics Bulletin previews the most noteworthy and anticipated events for May 2025.